TCT 422: Preclinical Assessment of a Novel Polymer-Free Hybrid Drug-Eluting Stent

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Alchimedics; AstraZenca; Biotronik; Boston Scientific Corporation; Cardiac Dimensions; Edwards Lifesciences; Medtronic; Recor Medical; Shockwave Medical; TriCares; Veryan
• Grant Support/Research Contract - InfraredX